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Summary
Family 18 chitinases play key roles in a range of path-
ogenic organisms and are overexpressed in the asth-
matic lung. By screening a library of marketed drug
molecules, we have identified methylxanthine deriva-
tives as possible inhibitor leads. These derivatives,
theophylline, caffeine, and pentoxifylline, are used ther-
apeutically as antiinflammatory agents, with pleiotropic
mechanisms of action. Here it is shown that they are
also competitive inhibitors against a fungal family 18
chitinase, with pentoxifylline being the most potent
(Ki of 37 M). Crystallographic analysis of chitinase-
inhibitor complexes revealed specific interactions
with the active site, mimicking the reaction intermedi-
ate analog, allosamidin. Mutagenesis identified the
key active site residues, conserved in mammalian
chitinases, which contribute to inhibitor affinity. En-
zyme assays also revealed that these methylxan-
thines are active against human chitinases.
Introduction
Chitin, a polymer of β(1,4)-linked N-acetylglucosamine
(GlcNAc), is an essential structural component of fungal
cell walls, the shells of nematode eggs, and arthropod
exoskeletons. Family 18 chitinases (CAZY GH 18 [1]),
which degrade this polymer, play key roles in the life
cycles of pathogenic fungi [2–4], nematodes [5], ma-
laria [6, 7], and insects [8–11]. In addition, a recent
study has shown that inhibition of a mammalian chi-
tinase associated with parasitic infections reduces re-
cruitment of inflammatory cells and profoundly damp-
ens T helper 2 (Th2) cellular responses in a murine
model of lung inflammation, suggesting that this en-
zyme may be a potential target for an asthma drug ther-
apy [12]. The enzymes have a conserved (β/α)8 fold,
with a surface groove containing exposed aromatic res-
idues, used for binding the chitin substrate [13–18].
Family 18 chitinases employ an unusual reaction mech-
anism, in which the acid protonating the glycosidic
bond is a conserved glutamate and the nucleophile is
the oxygen of the N-acetyl group on the −1 sugar (the*Correspondence: dava@davapc1.bioch.dundee.ac.uksugar on the nonreducing end of the glycosidic bond),
forming an oxazolinium ion intermediate [13, 15, 19]. A
range of chitinase inhibitors has been described, most
of which are natural products. Allosamidin is a pseudo-
trisaccharide that mimics the oxazolinium reaction in-
termediate, inhibiting family 18 chitinases in the nano-
molar-micromolar range [4, 8, 13, 15, 18, 20, 21]. Argifin,
argadin, and CI-4 are peptide-based inhibitors that
mimic protein-carbohydrate interactions, both in terms
of hydrogen bonds and stacking interactions [10, 11,
18, 22–25]. Unfortunately, all currently available inhibi-
tors have a number of properties that make them un-
suitable as inhibitor leads, including high molecular
weights (e.g., allosamidin, argifin, argadin), several ste-
reocenters, and low cLogP values (e.g., −5.2 for allo-
samidin). More importantly, there is only limited avail-
ability of family 18 chitinase inhibitors with an IC50 < 0.5
mM, hampering further inhibition studies of these en-
zymes.
To aid the development of potent, drug-like, and
readily available chitinase inhibitors, we have screened
a drug library, leading to the identification of methylxan-
thines as a potential scaffold. The drugs theophylline,
caffeine, and pentoxifylline, which contain the 1,3-
dimethylxanthine substructure, were studied in terms
of their inhibition and structural mode of binding
against a family 18 chitinase from the opportunistic
fungal pathogen Aspergillus fumigatus, showing that
pentoxifylline inhibits with a Ki of 37 M by forming
extensive π-π stacking interactions with conserved
tryptophans in the active site of this protein. The activ-
ity of mammalian chitinases, containing homologous
active site amino acid residues in their primary amino
acid sequences, are likewise inhibited by these xan-
thine derivatives.
Results
Inhibitor Screening
A commercially available library of 880 drug molecules
was screened at 100 M against a family 18 chitinase,
chitinase B1 from A. fumigatus (AfChiB1), using a fluo-
rescent assay (Figure 1A). After elimination of apparent
false positives (specifically, the hits in the far lower left
corner of Figure 1A), two methylxanthine derivatives,
theophylline and pentoxifylline, were identified, pos-
sessing a common 1,3-dimethylxanthine substructure,
which were the subject of further analyses. Inhibition by
theophylline and pentoxifylline, and the closely related
methylxanthine caffeine, was initially confirmed by
dose-response curves (Figure 1B), with IC50s ranging
from 1500 M (theophylline) to 126 M (pentoxifylline),
as presented in Table 1. Initial enzyme velocity measure-
ments at different concentrations of substrate (5–30 M)
and pentoxifylline (0, 60, 50, and 200 M) were used to
demonstrate that pentoxifylline is a competitive inhibi-
tor, with a Ki of 37 M (Figure 1C and Table 1).
Humans possess two family 18 chitinases, a chito-
triosidase (hCHT) [26] and acidic mammalian chitinase
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974Figure 1. Characterization of Theophylline, Caffeine, and Pentoxifylline Inhibition
(A) Results of the library screen, showing percentage remaining activity as measured by liberated 4-methylumbelliferone (horizontal axis)
versus absorbance measured at 360 nm (vertical axis), resulting from intrinsic absorbance at the excitation wavelength used for the fluores-
cence measurement. Hits in the lower left corner thus indicate compounds that do not themselves absorb at the excitation wavelength, yet
do show reduced fluorescence and, thus, reduced activity. Two hits, aminophylline (containing theophylline as active ingredient) and pentoxi-
fylline are indicated, together with their chemical structures.
(B) Dose-response curves for the methylxanthine inhibitors measured against AfChiB1.
(C) Lineweaver-Burk plots of pentoxifylline measured against AfChiB1 at different concentrations of the inhibitor. A fit of all the data against
a competitive inhibition model resulted in a Ki of 37 ± 2 M, with a Vmax of 0.0072 ± 0.0002 M/s and a Km of 12.9 ± 0.9 M.
(D) Tryptophan fluorescence binding experiments of pentoxifylline against wild-type and mutant AfChiB1. The data points, fluorescence with
λex=295 nm and λem=345 nm, were corrected for inner filter effects (due to absorbance of the xanthine at λex) using Fcorr = Fobs , 10(0.5 , A),
where A is the pentoxifylline absorbance at 295 nm. The data were then fitted with GraFit [49] to a single-site binding equation F/Fmax =
(C , [L])/(Kd + [L]), where C is the capacity and [L] is the ligand concentration. Experiments were performed in triplicate, except for the D175A,
E177A, and Y245F mutants, which were in duplicate.(AMCase), an enzyme with an unusual acidic pH opti-
mum [27], the in vivo elaboration of which is probably
evolutionarily tied to protective antiparasitic host re-
sponses to chitin-bearing pathogens. These enzymes,
like AfChiB1, are of the “bacterial” type of family 18
chitinases, possessing a deep catalytic cleft lined with
solvent-exposed aromatic residues [17], sharing 31%
and 28% sequence identity with AfChiB1, respectively.
Accordingly, the methylxanthines also inhibit the hu-
man chitinases, with IC50s up to 98 M, for pentoxifyl-
line (Table 1).
Among their pleiotropic mechanisms of action,
methylxanthine derivatives have also variously been re-
ported as phosphodiesterase inhibitors [28, 29], adeno-
sine receptor antagonists [30], and inducers of histone
deacetylase (HDAC) activity [31]. The inhibition of hu-
man phosphodiesterase-4 by theophylline, caffeine,
and pentoxifylline was measured using a PDE-SPA as-
say, and IC s were determined to be in the high M
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I50ange (Table 1), consistent with potencies published
lsewhere [32]. As a further control, inhibitory potential
f these xanthine derivatives was tested against two
ther glycoside hydrolases, lysozyme (using a fluores-
ein-based assay) and cellulase from Aspergillus niger
CAZY family GH 8 [1]), using a fluorescent substrate,
howing, at most, approximately 1 mM inhibition for
ellulase and none for lysozyme (Table 1). Similarly, al-
osamidin is known to not inhibit lysozyme [33]. To-
ether these data suggest that there may be a specific
fChiB1-pentoxifylline interaction, prompting us to in-
estigate the precise binding mode.
tructure of Chitinase-Inhibitor Complexes
o determine the mode of binding of theophylline, caf-
eine, and pentoxifylline to the fungal chitinase,
fChiB1 crystals were soaked with the inhibitors, fol-
owed by collection of X-ray diffraction data (Table 2).
n addition, a similar procedure was used to obtain a
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975Table 1. Methylxanthine Inhibition/Binding of Family 18 Chitinases, a Phosphodiesterase, and Two Control Glycoside Hydrolases
Theophylline Caffeine Pentoxifylline
AfChiB1 IC50 (M) 1500 ± 90 469 ± 23 126 ± 7 (Ki = 37 ± 2)
AfChiB1 Kd (M) — — 43 ± 10
AfChiB1-A217G Kd (M) — — 77 ± 9
AfChiB1-D175A Kd (M) — — 100 ± 8
AfChiB1-D246A Kd (M) — — 62 ± 23
AfChiB1-E322A Kd (M) — — 45 ± 9
AfChiB1-M243A Kd (M) — — 18 ± 1
AfChiB1-E177A Kd (M) — — 36 ± 7
AfChiB1-R301K Kd (M) — — 17 ± 3
AfChiB1-W137A Kd (M) — — n.d.a
AfChiB1-T138A Kd (M) — — 65 ± 34
AfChiB1-Y245F Kd (M) — — 64 ± 20
hCHT IC50 (M) >500 257 ± 8 98 ± 8
hAMCase activity at 1 mM (%) 36 36 49
Aspergillus niger cellulase IC50 (M) 1008 ± 159 1250 ± 278 881 ± 319
Egg white lysozyme activity at 500 M (%) 100 100 100
hPDE-4 IC50 (M) 386 ± 39 747 ± 212 168 ± 105
IC50s were determined as discussed in the text, and as shown for AfChiB1 in Figure 1B. The pentoxifylline Ki was determined by fitting all
data shown in Figure 1C to the standard equation for a competitive inhibitor (see legend to Figure 1C). The Kds were determined from
tryptophan fluorescence binding experiments, as shown and explained in Figure 1D.
a n.d. indicates that there was no detectable binding.to the GlcNAc subsite on the nonreducing end of the
Table 2. Details of Data Collection and Structure Refinement
Theophylline Caffeine Pentoxifylline Allosamidin
Resolution range (Å) 20–2.1 (2.17–2.1) 20–1.90 (1.97–1.90) 25–2.0 (2.07–2.0) 20–1.95 (2.02–1.95)
No. of Observed reflections 336,712 (30,248) 371,358 (34,086) 235,428 (19,469) 289,598 (27,689)
No. of Unique reflections 78,640 (7,728) 105,887 (10,440) 86,043 (7,767) 98782 (9,816)
Redundancy 4.3 (3.9) 3.5 (3.3) 2.7 (2.5) 2.9 (2.8)
I/σI 8.4 (2.6) 16.9 (4.2) 15.6 (2.6) 13.1 (2.2)
Completeness (%) 99.5 (98.0) 99.7 (98.9) 94.2 (85.5) 99.8 (99.7)
Rmerge 0.136 (0.540) 0.043 (0.301) 0.049 (0.384) 0.063 (0.563)
Rcryst, Rfree 0.185, 0.225 0.176, 0.202 0.187, 0.219 0.195, 0.224
Rmsd from ideal geometry
Bonds (Å) 0.01 0.01 0.008 0.007
Angles (°) 1.5 1.4 1.5 1.4
B factor rmsd (Å2)
Bonded, main chain 1.6 1.5 1.4 1.5
<B> proteina 28.2 24.2 27.4 28.7
<B> liganda 45.6 35.9 36.9 22.2
<B> watera 36.5 35.7 36.2 37.8
Values in parentheses are for the highest resolution shell. Crystals were of space group P41 and were cryo-cooled to 100 K. All measured
data were included in structure refinement.
a <B> = average B factor.
methylxanthine in the −1 subsite, an additional orderedcomplex of the well-known chitinase inhibitor allosami-
din [8] with AfChiB1. Allosamidin has been cocrystal-
lized with a range of chitinases and the mode of inhibi-
tion described in great detail [13, 20, 21, 34, 35]—the
structure is used here for comparison purposes only.
The methylxanthine-AfChiB1 complexes were refined
against high-resolution X-ray diffraction data (Table 2),
with the inhibitors well defined by unbiased |Fo| − |Fc|,
fcalc electron density maps (Figure 2). All three inhibi-
tors show the same surprising mode of binding, with a
common position for the methylxanthine substructure
(equivalent to theophylline). In the complex of AfChiB1
with theophylline, the weakest of the three inhibitors,
with an IC50 of 1500 M, the inhibitor binds in a position
equivalent to the allosamidin allosamizoline moiety
(Figure 2), termed the −1 position, as it is equivalentglycosidic bond [13, 15, 36, 37]. This allosamizoline
moiety is known to mimic the oxazolinium ion reaction
intermediate formed upon nucleophilic attack of the
N-acetyl oxygen on the anomeric carbon [15, 19]. The
methylxanthine core not only structurally mimics this
intermediate, but also makes similar interactions with
the chitinase. The xanthine ring appears to make favor-
able π-π stacking interactions with Trp385 (40 Å2 total
buried inhibitor surface), which is conserved in all
active family 18 chitinases, and also interacts with the
allosamizoline moiety in the allosamidin complex (Fig-
ure 2). Hydrogen bonds are formed with Asp175,
Tyr245, and the backbone nitrogen of Trp137, residues
all conserved in family 18 chitinases. Further water-
mediated hydrogen bonds are observed from the O2
oxygen to Asp246 and Arg301. In addition to the
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976Figure 2. Structures of the AfChiB1 Inhibitor Complexes
AfChiB1 residues lining the active site are shown as sticks with gray carbon atoms. Inhibitor molecules are shown as sticks with magenta
carbon atoms. Protein-inhibitor hydrogen bonds, calculated with PRODRG [48] and WHAT IF [52], are shown as dotted green lines. Unbiased
(i.e., before inclusion of any inhibitor model) |Fo| − |Fc|, fcalc electron density maps are shown at 2.5 σ. In the allosamidin complex, the sugar
subsites are labeled in blue from −3 to −1; the approximate positions of the +1 and +2 subsites are also shown.inhibitor molecule is observed occupying a position
equivalent to the −3 sugar in the allosamidin complex
(Figure 2). This additional methylxanthine molecule also
makes stacking interactions with a tryptophan (Trp52),
which is conserved in the other “bacterial”-type chi-
tinases (e.g., the human chitotriosidase [17], AMCase
[27], and chitinase A from Serratia marcescens [14, 37]).
Compared to theophylline, caffeine contains an addi-
tional 7-methyl group, which appears to increase inhibi-
tion 3-fold to an IC50 of 469 M. In the AfChiB1 complex
(Figure 2), caffeine binds identically to theophylline.
This is surprising, as the addition of a 7-methyl group
not only results in loss of the hydrogen bond for the
xanthine-N7 with Asp175, but also forces Asp175 in the
“down” conformation, compared to the “up” conforma-
tion in the allosamidin complex (Figure 2). Similarly,
Glu177 moves away to avoid steric clashes of the ter-
minal carboxylate with the N7-methyl. Again, an addi-
tional ordered inhibitor molecule is observed in the −3
subsite.
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anthine inhibitors against the fungal chitinase, with a
i of 37 M (Table 1). The AfChiB1-pentoxifylline com-
lex reveals several additional interactions, which may
xplain the order of magnitude increase in potency
ompared to caffeine (Figure 2). Strikingly, Trp137 ro-
ates 93° around χ1, sandwiching the xanthine moiety
ith extensive π-π stacking interactions (approximately
5 Å2 additional buried surface). The rotation of Trp137
xcludes an ordered water molecule seen in the theo-
hylline and caffeine complexes (Figure 2). Further-
ore, the pentoxifylline alkyl-aldehyde tail extends into
he −3 subsite, replacing the second ordered xanthine
een in both the theophylline and caffeine complexes,
tacking with Trp52 and hydrogen bonding two ordered
ater molecules (Figure 2).
To probe the contributions of individual residues in
he active site to pentoxifylline binding, interactions be-
ween mutant forms of AfChiB1 and the inhibitor were
easured with tryptophan fluorescence, exploiting the
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977large conformational change of Trp137 (Table 1 and Fig-
ure 1D). The Kd for pentoxifylline with the wild-type en-
zyme was determined to be 43 ± 10 M, which is in
good agreement with the Ki (37 ± 2 M) measured from
the kinetics experiment. Surprisingly, none of the mu-
tants show greater than 2.5-fold effects on binding,
with the exception of the Trp137Ala mutant, which ab-
rogates the detectable fluorescence quenching signal.
The two mutants that most increase affinity (about 2-fold)
are Met243Ala and Arg301Lys. Interestingly, Met243
sterically clashes with the inhibitor, with the shortest
distance being 3.2 Å (between pentoxifylline-N8 and
Met243-Sδ—the hydrogen atom on pentoxifylline-N8
would approach Met243-Sδ even closer), and mutation
to alanine relieves this clash (Figure 2). In allosamidin,
this unfavorable interaction with Met243 does not exist
due to the “kink” between the two five-membered
rings, whereas the pentoxifylline purine is flat (Figure
2). Similarly, the Arg301Lys mutant may increase bind-
ing as the flipped Trp137 indole ring closely approaches
the Arg301 guanidinium group (shortest distance, 3.8
Å from Trp137-Cη2 to Arg301-Nη2; Figure 2). The two
mutants that most decrease affinity (about 2-fold) are
Asp175Ala and Ala217Gly. Ala217 forms the bottom of
the pocket for the methyls on allosamidin’s allosamizo-
line moiety; mutation to an alanine could lead to a large
unoccupied pocket below the pentoxifylline purine ring.
Similarly, mutation of Asp175 to Ala would cause the
purine ring to bury the unsatisfied hydrogen bond do-
nor Tyr48 (Figure 2). Strikingly, the Y245F mutation,
which removes the only direct side-chain inhibitor hy-
drogen bond observed in the complex, only reduces the
affinity 1.5-fold (Figure 2, Table 1).
Discussion
Using a screening approach, several methylxanthines
were identified that inhibit family 18 chitinases, the
most potent being pentoxifylline, showing a Ki of up to
37 M against the chitinase AfChiB1 from the fungal
pathogen A. fumigatus. These molecules are small and
drug-like and make extensive hydrogen bonding and
π-π stacking interactions with the active site, which ap-
pear to be unique to the chitinase, as the other glycosi-
dases tested show only poor inhibition. The largest of
these inhibitors, pentoxifylline, only covers a small part
of the AfChiB1 active site, from the −1 to just beyond
the −2 subsite. By comparison, other more potent chi-
tinase inhibitors, such as allosamidin (which covers the
−1 to −3 subsites, Figure 2) and argifin/argadin (which
cover the −1 to +2 subsites [18, 23]) occupy further
subsites. It should be noted that nearly all residues in
the −1 subsite are identical in the “bacterial”- and
“plant”-types of chitinases [35], suggesting these inhib-
itors may also reduce activity of the latter class of en-
zymes.
Previous analyses of the binding mode of methylxan-
thines in the phosphodiesterases show that the N1-
methyl projects into a small pocket, suggesting that
there is no additional space to derivatize much beyond
the pentoxifylline side chain [38, 39]. Thus, it should
be possible to extend the methylxanthine scaffold to
address the additional available chitinase subsites andincrease chitinase affinity and selectivity through syn-
thetically accessible purine chemistry. Molecules of this
nature may help elucidate the role that chitinases play
in fungal morphology, growth, and virulence. Similarly,
this approach may extend to the study of the precise
functions of the mammalian chitinases. In this regard,
chitotriosidase and acidic mammalian chitinase, as well
as several structurally related, more family 18 chitinase-
like lectins (chilectins), purported to be involved in car-
bohydrate recognition, such as HCgp-39, YM-1, and
YM-2, have been implicated in the pathophysiology of
inflammation (reviewed in [40]). Chitotriosidase is ex-
pressed in activated macrophages, and its levels are
known to be upregulated both in atherosclerosis and
in patients with Gaucher’s lipid storage disease [26].
Acidic mammalian chitinase expression has been shown
to be upregulated in the lungs of asthmatics, as well as
in mice that develop airway hyperresponsiveness fol-
lowing antigen sensitization and challenge [12]. In the
latter instance, inhibitors of AMCase (neutralizing anti-
sera, allosamidin) efficaciously decreased airway hy-
perresponsiveness, reduced inflammatory cell influx
into bronchiolar alveolar lavage fluid, and ameliorated
airway inflammation. Anti-inflammatory effects of methyl-
xanthine derivatives in vivo have already been well doc-
umented. For instance, theophylline has a greater than
50-year history as an asthma drug and acts not only as
a bronchodilator, but also as an immunomodulator that
downregulates the function of inflammatory cells in vi-
tro and in vivo (reviewed in [41]). Pentoxifylline, a drug
used clinically to treat peripheral vascular disease, like-
wise has immune-modulating properties [42, 43], in-
cluding the ability to suppress inflammatory cytokine
production. This drug has also been demonstrated to
blunt airway hyperresponsiveness during allergen sen-
sitization in rodent models of allergic inflammation [44].
The proposed mechanisms of action for theophylline
and pentoxifylline action thought to occur at clinically
relevant drug concentrations are nonspecific phospho-
diesterase isozyme inhibition and nonselective antago-
nism of adenosine receptors [28–30]. Future research
could investigate whether the methylxanthine deriva-
tives identified here affect chitinase activity in an anti-
asthma setting.
Significance
Family 18 chitinases play key roles in a range of chi-
tin-containing pathogenic organisms and are over-
expressed in the asthmatic lung. So far, no drug-like
inhibitors for this family of enzymes have been de-
scribed. This article reports the results of a screen
against a library of drug molecules, identifying the
methylxanthine drugs theophylline, caffeine, and pen-
toxifylline as micromolar inhibitors. These molecules
show an unexpected binding mode involving exten-
sive stacking interactions, and provide attractive,
synthetically accessible scaffolds for further optimi-
zation.
Experimental Procedures
Purification, Crystallization, and Structure Determination
AfChiB1 was expressed, purified, and crystallized as previously de-
scribed [18]. Briefly, AfChiB1 was overexpressed as a GST-fusion
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978protein in Escherichia coli and purified using a combination of affin-
ity and size-exclusion chromatography. Pure AfChiB1 protein in 50
mM TRIS/HCl (pH 8) was spin-concentrated to 28 mg/ml. Vapor
diffusion crystallization experiments were set up by mixing 1 l of
protein and 1 l of mother liquor, consisting of 0.1 M Tris/HCl (pH
9.5) and 1.4 M Li2SO4, and equilibrated against a reservoir contain-
ing 0.5 ml of mother liquor. Crystals used for soaking experiments
were washed three times in 0.1 M sodium citrate (pH 5.5) and 1.4
M Li2SO4, and thereafter soaked in mother liquor containing 3.8,
3.8, 20.0, and 9.0 mM ligand, with soaking times of 20, 5, 10, and
30 min for the theophylline, caffeine, pentoxifylline, and allosamidin
inhibitors, respectively. The crystals were cryoprotected by a 10 s
immersion in 3 M Li2SO4 and frozen in a nitrogen cryostream for
data collection. Data were collected on a rotating anode and pro-
cessed with the HKL suite of programs [45].
Refinement of the AfChiB1-inhibitor complexes was performed
with CNS [46] interspersed with model building in O [47], starting
from the native AfChiB structure (PDB entry 1W9P [18]). Models for
the ligands were not included until their conformations were well
defined by the unbiased |Fo| − |Fc|, fcalc electron density maps (Fig-
ure 2). Due to the relatively high inhibitor concentrations used for
soaking, electron density for additional, less ordered inhibitor
molecules appear out with the −1 subsite. In the interest of simplic-
ity, differences between the complexes are discussed using the
first AfChiB monomer in the coordinate files, and analysis of inhibi-
tor binding is focused on the active site only. Topologies for the
ligands were obtained from the PRODRG server [48]. Images were
generated with PyMol (available online at: http://www.pymol.org).
AfChiB1 Enzymology and Mutagenesis
AfChiB1 inhibition was studied using the fluorogenic substrate
4-methylumbelliferyl-β-D-N,N#-diacetylchitobiose (4MU-GlcNAc2;
Sigma Chemical, St. Louis, MO), following hydrolysis measuring lib-
erated, fluorescent 4-methylumbelliferone (4MU), as described pre-
viously [18]. Briefly, in a final volume of 50 l, 2 nM of enzyme was
incubated with 20 M substrate in McIlvain buffer (100 mM citric
acid, 200 mM sodium phosphate [pH 5.5]) containing 0.1 mg/ml
BSA, for 10 min at 37°C in the presence of different concentration
of inhibitors. After the addition of 25 l of 3 M glycine-NaOH (pH
10.3), the fluorescence of the liberated 4MU was quantified using
a Flx 800 microtiterplate fluorescence reader (Bio-Tek Instruments),
with excitation and emission wavelengths of 360 nm and 460 nm,
respectively, using 40 nm slits. Experiments were performed in trip-
licate. Production of 4MU was linear with time for the incubation
period used, and less than 10% of available substrate was hy-
drolyzed.
AfChiB1 was screened against a small molecule library of 880
compounds (Prestwick Chemical, France). The library was screened
with 50 l assay volumes in 96-well plates using 2 nM of enzyme,
0.1 mg/ml BSA, and 20 M substrate and 100 M inhibitor, assum-
ing a compound molecular weight of 500 Da. To remove false posi-
tives of compounds that absorb at the excitation wavelength used
for measuring 4MU concentration (and thus enzyme activity), ab-
sorbance at the excitation wavelength (360 nm) was also moni-
tored.
For the determination of the mode of inhibition of pentoxifylline,
reactions followed the same protocol, using 5-30 M substrate in
the presence of increasing amounts of the inhibitor. The mode of
action was determined by plotting the data as Lineweaver-Burk
plots, and by fitting all data to the standard competitive inhibition
equation with GraFit software [49].
A range of AfChiB1 point mutants were used to assess effects
on inhibition—the construction, purification, and kinetic analysis of
these mutants have been reported previously [18].
PDE, Lysozyme, Cellulase, and Mammalian
Chitinase Enzymology
Commercially available cellulase from A. niger (Sigma: C-1184) was
assayed using the fluorogenic substrate 4-methylumbelliferyl-β-D-
cellobioside (Sigma: M-6018). In a final volume of 50 l, 5 nM of
enzyme was incubated with 20 M substrate in McIlvain buffer,
containing 0.1 mg/ml BSA, for 30 min at 37°C in the presence of
different concentration of inhibitors. After the addition of 25 l of 3
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Rglycine-NaOH (pH 10.3), the fluorescence of the liberated 4MU
as quantified using a fluorescence reader with parameters as for
he AfChiB1 experiments. Measurements were performed in tripli-
ate. Production of 4MU was linear with time for the incubation
eriod used, and less than 10% of available substrate was hy-
rolyzed.
Phosphodiesterase 4A (PDE4A) was assayed using an Sf9-
xpressed GST-fusion, and activity was monitored by hydrolysis
f [3H]cAMP to [3H]AMP using the PDE-SPA kit from Amersham
harmacia Biotech, as described previously [50]. The assay reac-
ion contained 100 nM [3H]cAMP (1 Ci/ml) in solution containing
0 mM HEPES (pH 7.5), 10 mM MgCl2, 100 mM EDTA, 100mM KCl,
nd 2 l of test compound in DMSO at 30°C. The reaction was
nitiated by addition of enzyme and run for 10 min. The potency
f inhibitors (IC50) was determined from a dose-response curve.
xperiments were performed with n = 6.
Lysozyme was assayed using the EnzCheck Lysozyme kit from
olecular Probes, as described by the manufacturer. Chicken egg
hite lysozyme and its substrate, fluorescein-labeled Micrococcus
ysodeikyius cell wall (DQ lysozyme substrate) were used to deter-
ine compound inhibition. Briefly, 6.25 U of lysozyme were incu-
ated with 25 g of DQ substrate with or without various concen-
rations of inhibitor in a total volume of 100 l at 37°C for 30 min.
he fluorescence was determined using excitation and emission
avelengths of 360 and 460 nm, respectively. The IC50 was deter-
ined from a dose-response curve. Experiments were performed
n triplicate.
Gene sequences for the human chitotriosidase and AMCase are
nown [51, 27]. cDNAs encoding human chitotriosidase and human
MCase were generated from total human lung RNA using RT-PCR
nd primers based on the published sequence (primer pairs: 5#-gcc
ccatggtgcggtctgtggcctgggcaggtttc-3# and 5#-tcaattccaggtgcagc
tttgcaggagttgctg-3# for chitotriosidase: 5#-gccaccatgacaaagctt
ttctcctcacaggtcttg-3# and 5#-ttatgcccagttgcagcaatcacagctggtgt
gaag-3# for AMCase), then subcloned into p3xFLAG-CMV-13 vec-
or (Sigma). The vector encodes three adjacent FLAG epitopes
ownstream of the cloning region. Plasmids encoding FLAG-tagged
hitotriosidase and hAMCase were then transiently transfected into
EK 293 cells and supernatants harvested 3 or 6 d after transfec-
ion. FLAG-tagged expressing proteins were purified over an anti-
LAG M2 gel affinity column and eluted with a 3XFLAG peptide
ccording to the manufacturer’s instructions. Inhibitor potencies
ere determined for the purified proteins using the chitinase assay
imilar to the one described above. Briefly, the assay consisted of
luorogenic substrate 4MU-GlcNAc2 (Sigma) at a final concentra-
ion of 22 M, along with 1 nM of enzyme in a final volume of
00 l. The fluorescence was read using excitation and emission
avelengths of 355 and 460 nm, respectively. The buffers were the
ame as described above for fungal chitinase, and the reaction was
arried out at 30°C for 30 min.
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